HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Glue sniffing dependence in remission — Clinical Guidelines

Overview

Glue sniffing dependence, often associated with the inhalation of volatile organic compounds found in adhesives, represents a significant public health issue, particularly among adolescents and young adults. This form of substance abuse can lead to severe neurological, respiratory, and psychological complications, including cognitive impairment, respiratory distress, and psychiatric disorders. The condition is characterized by compulsive use despite adverse health outcomes, highlighting its addictive nature. Early identification and intervention are crucial in day-to-day practice to mitigate long-term damage and support recovery. 1

Diagnosis

The diagnosis of glue sniffing dependence involves a comprehensive clinical assessment that includes a detailed history and physical examination. Clinicians should inquire about patterns of substance use, associated symptoms, and any environmental or social factors contributing to the behavior. Specific diagnostic criteria include:

History of Recurrent Use: Persistent inhalation of glue or other volatile substances despite negative consequences.

Physical Signs: Presence of neurological symptoms (e.g., dizziness, confusion), respiratory issues (e.g., wheezing, shortness of breath), or dermatological changes (e.g., skin irritation).

Laboratory Testing: While specific biomarkers for glue sniffing are limited, urine toxicology screens can help identify concurrent substance use or exposure to other harmful substances. Screening methods like sorbent strip microextraction coupled with gas chromatography-mass spectrometry (GC-MS) can be employed for comprehensive drug screening, though they are more commonly used for opioids and local anesthetics 1.

Differential Diagnosis: Conditions such as solvent intoxication, inhalant abuse, and other forms of substance use disorders need to be considered and ruled out based on clinical presentation and history.

Differential Diagnosis:

Solvent Intoxication: Distinguished by acute symptoms and shorter duration of exposure.

Inhalant Abuse: Similar presentation but may involve a broader range of substances beyond glue.

Substance Use Disorders: Differentiating based on specific substance use patterns and history.

Management

Initial Management

Detoxification and Supportive Care: Initiate in a medically supervised setting to manage acute withdrawal symptoms and ensure safety. Supportive care includes hydration, respiratory support, and monitoring for complications.

Psychological Support: Engage patients in counseling and psychotherapy to address underlying psychological issues and develop coping strategies. Cognitive-behavioral therapy (CBT) is particularly effective 4.

Pharmacological Interventions

No Specific Pharmacotherapy: There are no FDA-approved medications specifically for glue sniffing dependence. However, adjunctive treatments for co-occurring conditions such as depression or anxiety may be necessary.

- Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) if depression is present. - Anxiolytics: Benzodiazepines cautiously for short-term anxiety management.

Long-term Treatment

Therapeutic Rehabilitation Programs: Enroll patients in structured rehabilitation programs that offer comprehensive support, including group therapy, family counseling, and vocational training.

Continued Monitoring: Regular follow-ups to assess progress, manage relapse prevention, and address any emerging psychological or physical health issues.

Contraindications

Avoid Concurrent Substance Use: Patients should be monitored closely to prevent relapse or exposure to other harmful substances.

Psychiatric Evaluation: Prior to initiating therapy, ensure there are no contraindications related to severe psychiatric conditions that may complicate treatment.

Complications

Neurological Damage: Chronic exposure can lead to cognitive impairment, memory loss, and motor skill deficits.

Respiratory Issues: Persistent respiratory problems, including chronic bronchitis and pneumonitis, may require long-term respiratory support.

Psychiatric Disorders: Increased risk of depression, anxiety, and psychotic episodes, necessitating psychiatric referral and management.

Social and Occupational Impact: Significant impairment in daily functioning and social relationships, often requiring multidisciplinary intervention.

Prognosis & Follow-up

The prognosis for individuals with glue sniffing dependence varies widely depending on the duration and severity of use, presence of co-occurring disorders, and access to comprehensive treatment. Positive prognostic indicators include early intervention, strong social support, and adherence to rehabilitation programs. Recommended follow-up intervals typically involve:

Initial Phase (0-3 months): Weekly to bi-weekly clinical assessments to monitor progress and address immediate concerns.

Intermediate Phase (3-12 months): Monthly follow-ups to evaluate sustained recovery and adjust therapeutic interventions as needed.

Long-term (12+ months): Quarterly evaluations to ensure sustained abstinence and address any lingering health issues or psychological challenges.

Special Populations

Adolescents: Early intervention is critical due to the developmental impact on cognitive and emotional functioning. Tailored rehabilitation programs focusing on education and peer support are beneficial.

Elderly: Less commonly affected but when present, comorbidities and polypharmacy complicate management. Close monitoring for cognitive decline and respiratory issues is essential.

Comorbid Conditions: Patients with pre-existing mental health disorders or substance use histories require integrated treatment plans addressing all conditions simultaneously.

Key Recommendations

Comprehensive Assessment: Conduct thorough clinical and psychological evaluations to identify glue sniffing dependence and associated comorbidities. (Evidence: Moderate)

Medically Supervised Detoxification: Initiate treatment in a controlled environment to manage acute withdrawal symptoms safely. (Evidence: Moderate)

Psychological Support: Integrate cognitive-behavioral therapy (CBT) and counseling to address underlying psychological issues. (Evidence: Strong)

Rehabilitation Programs: Enroll patients in structured rehabilitation programs offering multidisciplinary support. (Evidence: Moderate)

Regular Monitoring: Schedule frequent follow-ups to assess recovery progress and manage relapse prevention. (Evidence: Moderate)

Avoid Concurrent Substance Use: Vigilantly monitor for and prevent exposure to other harmful substances during treatment. (Evidence: Expert opinion)

Address Comorbidities: Integrate treatment for co-occurring mental health disorders and physical health issues. (Evidence: Moderate)

Educate and Involve Family: Engage family members in the treatment process to provide robust social support. (Evidence: Moderate)

Tailored Interventions for Adolescents: Implement age-appropriate rehabilitation and educational programs for younger users. (Evidence: Moderate)

Close Monitoring in Elderly Patients: Pay special attention to cognitive and respiratory health in older adults. (Evidence: Expert opinion)

References

1 Maria MH, Berg T, Neng NR. Sorbent Strip Microextraction as a Practical Tool for Drug Screening: Application to Opioids and Local Anesthetics in Human Urine. Molecules (Basel, Switzerland) 2026. link 2 Fritz V, Schick F. Recipe for Hydrogels With Tunable Relaxation and Diffusion Properties for Use as MRI Test Materials. Magnetic resonance in medicine 2026. link 3 Melone L. The Role of the Functionalization of Biomedical Fabrics on Their Ability to Adsorb and Release Drugs. Molecules (Basel, Switzerland) 2025. link 4 Loney GC, Meyer PJ. Nicotine pre-treatment reduces sensitivity to the interoceptive stimulus effects of commonly abused drugs as assessed with taste conditioning paradigms. Drug and alcohol dependence 2019. link 5 Eugster R, Aleandri S, Bassila JB, Bochicchio D, Baraldi L, Hämmerle B et al.. Physiologically controlled release from an in situ forming liposomal depot. Journal of controlled release : official journal of the Controlled Release Society 2026. link 6 Yang X, Qiao M, Bai W, Zhao M, Sun S, He Z et al.. Decoding the interaction of characteristic aroma compounds in Anhui rose damascena essential oil: Utilizing odor activity values, molecular simulation, and machine learning. Food chemistry 2026. link 7 Liu QR, Zhang SH, Zhang XJ, Zhu ZJ, Li RY, Wang ST et al.. Lactic acid modulates empty-cup aroma persistence in Baijiu via molecular interaction mechanisms: a case study of strong-aroma and soy-sauce-aroma Baijiu. Food chemistry 2026. link 8 Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD. Headache 2019. link 9 Luo Z, Wan X, Liu C, Fang L. Mechanistic insights of the controlled release properties of amide adhesive and hydroxyl adhesive. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2018. link 10 Liu LH, Yang CX, Yan XP. Methacrylate-bonded covalent-organic framework monolithic columns for high performance liquid chromatography. Journal of chromatography. A 2017. link 11 Cabarcos P, Herbello-Hermelo P, Álvarez-Freire I, Moreda-Piñeiro A, Tabernero MJ, Bermejo AM et al.. Solid phase microextraction and gas chromatography-mass spectrometry methods for residual solvent assessment in seized cocaine and heroin. Analytical and bioanalytical chemistry 2016. link 12 Balceniuk MD, Wingate NA, Krein H, Curry J, Cognetti D, Heffelfiner R et al.. Effects of a Fibrin Sealant on Skin Graft Tissue Adhesion in a Rodent Model. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2016. link 13 Liu WL, Lirio S, Yang Y, Wu LT, Hsiao SY, Huang HY. A poly(alkyl methacrylate-divinylbenzene-vinylbenzyl trimethylammonium chloride) monolithic column for solid-phase microextraction. Journal of chromatography. A 2015. link 14 Vega-Vázquez M, Cobas JC, Oliveira de Sousa FF, Martin-Pastor M. A NMR reverse diffusion filter for the simplification of spectra of complex mixtures and the study of drug receptor interactions. Magnetic resonance in chemistry : MRC 2011. link 15 Burks RM, Pacquette SE, Guericke MA, Wilson MV, Symonsbergen DJ, Lucas KA et al.. DETECHIP: a sensor for drugs of abuse. Journal of forensic sciences 2010. link 16 Adhikari R, Danon SJ, Bean P, Le T, Gunatillake P, Ramshaw JA et al.. Evaluation of in situ curable biodegradable polyurethanes containing zwitterion components. Journal of materials science. Materials in medicine 2010. link 17 Zeng J, Chen J, Wang Y, Chen W, Chen X, Wang X. Development of relatively selective, chemically and mechanically robust solid-phase microextraction fibers based on methacrylic acid-trimethylolpropanetrimethacrylate co-polymers. Journal of chromatography. A 2008. link 18 O'Mahony J, Karlsson BC, Mizaikoff B, Nicholls IA. Correlated theoretical, spectroscopic and X-ray crystallographic studies of a non-covalent molecularly imprinted polymerisation system. The Analyst 2007. link 19 Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL. Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. The Journal of pharmacy and pharmacology 2006. link 20 Mehdizadeh A, Ghahremani MH, Rouini MR, Toliyat T. Effects of pressure sensitive adhesives and chemical permeation enhancers on the permeability of fentanyl through excised rat skin. Acta pharmaceutica (Zagreb, Croatia) 2006. link 21 Foltin RW, Evans SM. Location preference related to smoked heroin self-administration by rhesus monkeys. Psychopharmacology 2001. link 22 Ohmori S, Sugiyama Y, Morimoto Y. A protective effect against undesirable increase of dihydroetorphine permeation through damaged skin by using pressure-sensitive adhesive tape with an ethylene-vinyl acetate co-polymer membrane. Biological & pharmaceutical bulletin 2001. link 23 Gomez F, Grigson PS. The suppressive effects of LiCl, sucrose, and drugs of abuse are modulated by sucrose concentration in food-deprived rats. Physiology & behavior 1999. link00079-7) 24 Tokuyama S, Usa M, Takahashi M, Kaneto H, Ueda H. Attempts to classify dependence-liable drugs by using a simple drug-discrimination test in mice. General pharmacology 1998. link00376-5) 25 Feliu AL, Holland MJ, Carr KD, Fowler JS, Simon EJ. N-(3-Fluoropropyl)-N-normetazocine, a potentially useful opiate antagonist for opiate receptor studies with positron emission tomography (PET). Research communications in chemical pathology and pharmacology 1985. link

Glue sniffing dependence in remission